DDInter576 DDInter703
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph.
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Etravirine
Disulfiram {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Etravirine
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Disulfiram {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Disulfiram {u} (Compound) causes {v} (Side Effect) Hepatic failure
Hepatic failure {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Disulfiram {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Disulfiram {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etravirine (Compound)
Disulfiram (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Disulfiram (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Disulfiram (Compound) causes Hepatic failure (Side Effect) and Hepatic failure (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Disulfiram (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Disulfiram (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Etravirine